Resultados de Búsqueda por Autor

artículo

STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)

Publicado por
Cordeiro de Lima, VC, Corassa, M, Saldanha, E, Freitas, H, Arrieta, O, Raez, L, Samtani, S, Ramos, M, Rojas, C, Burotto, M, Chamorro, DF, Recondo, G, Ruiz-Patiño, A, Más López, L, Zatarain-Barrón, L, Mejía, S, Nicolas Minata, J, Martín, C, Bautista Blaquier, J, Motta Guerrero, R, Aliaga-Macha, C, Carracedo-Gonzales, C, Ordóñez-Reyes, C, Garcia-Robledo, JE, Corrales, L, Sotelo, C, Ricaurte, L, Santoyo, N, Cuello, M, Jaller, E, Rodríguez, J, Archila, P, Bermudez, M, Gamez, T, Russo, A, Viola, L, Malapelle, U, de Miguel Perez, D, Rolfo, C, Rosell, R, Cardona, AF

Publicado 2022

Enlace

Background: Mutations in STK11 (STK11Mut) and, frequently co-occurring, KEAP1 mutations (KEAP1Mut) are associated with poor survival in metastatic Non-small Cell Lung Cancer (mNSCLC) patients treated with immunotherapy. However, there are limited data regarding the prognostic or predictive significance of these genomic alterations among Hispanics. Methods: This retrospective study analyzed a cohort of Hispanic patients (N = 103) diagnosed with mNSCLC from the US and seven Latin American countries (LATAM) treated with immune checkpoint inhibitors (ICI) alone or in combination as first-line (Cohort A). All cases were treated in routine care between January 2016 and December 2021. The main objectives were to determine the association of mutations in STK11 or KEAP1 in these patients’ tumors with overall (OS) and progression-free survival (PFS), presence of KRAS mutations, tumor mutational ...